Genmab — Director's Dealing 2016

Aug 17, 2016

Company Announcement

Copenhagen, Denmark; August 17, 2016 – In accordance with Article 19 of
Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523,
the persons below have given Genmab A/S (Nasdaq Copenhagen: GEN) power of
attorney on their behalf to publish and report their trading in Genmab shares
and related instruments, as follows:

1. Details of the person discharging managerial responsibilities / person
   closely associated

---

a) Name Jan van de
Winkel

---

2. Reason for the notification

a) Position/status President
& Chief
Executive
Officer

---

b) Initial notification/Amendment Initial
notificatio
n

---

1. Details of the issuer, emission allowance market participant, auction
   platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for (i) each type of
   instrument; (ii) each type of transaction; (iii) each date; and (iv) each
   place where transactions have been conducted

---

a) Description of the financial instrument, type of instrument Share
Identification code DK0010272202

---

b) Nature of the transaction Subscription
of shares
(exercise
of
warrants)

---

c) Price(s) and volume(s) Price(s)
Volume(s)DKK
80.55
10,000
DKK 352.50
100,000

---

d) Aggregated information 110,000
- Aggregated volume shares
- Price DKK 327.78

---

e) Date of the transaction 2016-08-17

f) Place of the transaction Outside a
market
place

---

1. Details of the person discharging managerial responsibilities / person
   closely associated

---

a) Name David A.
Eatwell

---

2. Reason for the notification

a) Position/status Executive
Vice
President
& Chief
Financial
Officer

---

b) Initial notification/Amendment Initial
notificatio
n

---

1. Details of the issuer, emission allowance market participant, auction
   platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for (i) each type of
   instrument; (ii) each type of transaction; (iii) each date; and (iv) each
   place where transactions have been conducted

---

a) Description of the financial instrument, type of instrument Share
Identification code DK0010272202

---

b) Nature of the transaction Subscription
of shares
(exercise
of
warrants)

---

c) Price(s) and volume(s) Price(s)
Volume(s)DKK
40.41
40,000

---

d) Aggregated information
- Aggregated volume
- Price

---

e) Date of the transaction 2016-08-17

f) Place of the transaction Outside a
market
place

---

1. Details of the person discharging managerial responsibilities / person
   closely associated

---

a) Name Anders
Gersel
Pedersen

---

2. Reason for the notification

a) Position/status Board member

b) Initial notification/Amendment Initial
notificatio
n

---

1. Details of the issuer, emission allowance market participant, auction
   platform, auctioneer or auction monitor

---

a) Name Genmab A/S

b) LEI-code N/A

1. Details of the transaction(s): section to be repeated for (i) each type of
   instrument; (ii) each type of transaction; (iii) each date; and (iv) each
   place where transactions have been conducted

---

a) Description of the financial instrument, type of instrument Share
Identification code DK0010272202

---

b) Nature of the transaction Subscription
of shares
(exercise
of
warrants)

---

c) Price(s) and volume(s) Price(s)
Volume(s)DKK
174
1,500
DKK 272
12,000

---

d) Aggregated information 13,500
- Aggregated volume shares
- Price DKK 261.11

---

e) Date of the transaction 2016-08-17

f) Place of the transaction Outside a
market
place

---

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia
indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated
or double refractory multiple myeloma. Daratumumab is in clinical development
for additional multiple myeloma indications and for non-Hodgkin’s lymphoma.
Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's
technology base consists of validated and proprietary next generation antibody
technologies - the DuoBody® platform for generation of bispecific antibodies,
and the HexaBody® platform which creates effector function enhanced antibodies.
The company intends to leverage these technologies to create opportunities for
full or co-ownership of future products. Genmab has alliances with top tier
pharmaceutical and biotechnology companies. For more information visit
www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo™;
the DuoBody logo®; the HexaBody logo™; HuMax®; HuMax-CD20®; DuoBody®; HexaBody®
and UniBody®. Arzerra® is a trademark of Novartis AG or its affiliates.
DARZALEX® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 35
CVR no. 2102 3884

Genmab A/S
Bredgade 34E
1260 Copenhagen K
Denmark